ArticleKidney medicine2026
Outcomes and Risk Factors of Widened Difference in Estimated Glomerular Filtration Rate Based on Creatinine or Cystatin C: Adjust Model Development With More Than 300,000 UK Biobank Participants.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale & Objective: Recent studies have highlighted the clinical significance of the discrepancies between cystatin C--based CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) estimated glomerular filtration rate (eGFR) (eGFRcys) and creatinine-based CKD-EPI eGFR (eGFRcr). This study explores the implications of the differences between eGFRcys and eGFRcr (eGFRdiff) on clinical outcomes and aims to develop an adjustment model using eGFRcr and associated clinical variables. Study Design: Retrospective cohort study. Setting & Participants: A total of 343,854 UK Biobank participants. Exposure: eGFRdiff (mL/min/1.73 m Outcome: Death, myocardial infarction (MI), and ischemic stroke. Analytical Approach: We analyzed the risks of death, MI, and ischemic stroke in groups with eGFRdiff < -15 and eGFRdiff > 15 using Cox proportional hazards models. Logistic regression analysis was used to identify variables associated with eGFRdiff. In addition, we developed and validated a regression model using eGFRcr and variables associated with eGFRdiff to approximate eGFR with optimal performance. Results: Individuals with eGFRdiff < -15 were associated with increased risks of death (HR, 1.37 [1.30-1.44]), MI (HR, 1.23 [1.15-1.33]), and ischemic stroke (HR, 1.19 [1.08-1.31]). Variables associated with eGFRdiff < -15 included high waist/hip circumference, high body weight, low fat-free mass, high fat/carbohydrate intake, low protein intake, diabetes, and smaller kidney volumes. A simplified regression model approximating eGFRcys was developed, using only eGFRcr, sex, age, height, weight, and body mass index. In the validation, applying the simplified linear model to eGFRcr significantly enhanced its correlation with eGFRcys and improved clinical outcome prediction, as demonstrated by favorable net reclassification indices for death, MI, and ischemic stroke. Limitations: The absence of true GFR data. Conclusions: This study confirmed that eGFRdiff < -15 is associated with increased risks of clinical outcomes and identified diverse factors associated with eGFRdiff. We developed an adjusted model to approximate eGFRcr to eGFRcys, demonstrating superior clinical outcome association using the adjusted values.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.